Bone Marrow Research [60] S. H. Koh, H. S. Choi, E. S. Park, H. J. Kang, H. S. Ahn, and H. Y. Shin, “Co-culture of human CD34+ cells with mesenchymal stem cells increases the survival of CD34+ cells against the 5-aza-deoxycytidine- or trichostatin A-induced cell death,” Biochemical and Biophysical Research Communications, vol. 329, no. 3, pp. 1039–1045, 2005. [61] M. Tabata, A. Satake, N. Okura et al., “Long-term outcome after allogeneic bone marrow transplantation for hemato- logical malignancies with non-remission status. Results of a single-center study of 24 patients,” Annals of Hematology, vol. 81, no. 10, pp. 582–587, 2002. [62] L. M. Ball, M. E. Bernardo, H. Roelofs et al., “Cotransplanta- tion of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation,” Blood, vol. 110, no. 7, pp. 2764–2767, 2007. [63] S. Hombach-Klonisch, S. Panigrahi, I. Rashedi et al., “Adult stem cells and their trans-diﬀerentiation potential- perspectives and therapeutic applications,” Journal of Molec- ular Medicine, vol. 86, no. 12, pp. 1301–1314, 2008. [64] R. Iannone, J. F. Casella, E. J. Fuchs et al., “Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia,” Biology of Blood and Marrow Transplantation, vol. 9, no. 8, pp. 519–528, 2003. [65] S. Y. Pai, D. DeMartiis, C. Forino et al., “Stem cell trans- plantation for the Wiskott-Aldrich syndrome: a single-center experience conﬁrms eﬃcacy of matched unrelated donor transplantation,” Biology of Blood and Marrow Transplanta- tion, vol. 38, no. 10, pp. 671–679, 2006. [66] C. Peters and W. Krivit, “Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome),” Bone Marrow Transplantation, vol. 25, no. 10, pp. 1097–1099, 2000. [67] M. Salerno, R. Busiello, V. Esposito et al., “Allogeneic bone marrow transplantation restores IGF-I production and linear growth in a γ-SCID patient with abnormal growth hormone receptor signaling,” Bone Marrow Transplantation, vol. 33, no. 7, pp. 773–775, 2004. [68] S. L. Staba, M. L. Escolar, M. Poe et al., “Cord-blood transplants from unrelated donors in patients with hurler’s syndrome,” New England Journal of Medicine, vol. 350, no. 19, pp. 1960–1969, 2004. [69] T. Kurokawa, K. Fischer, H. Bertz, S. Hoegerle, J. Finke, and A. Mackensen, “In vitro and in vivo characterization of graft- versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation,” International Journal of Cancer, vol. 101, no. 1, pp. 52–60, 2002. [70] B. Maitra, E. Szekely, K. Gjini et al., “Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation,” Bone Marrow Transplantation, vol. 33, no. 6, pp. 597–604, 2004. [71] I. Resnick, P. Stepensky, G. Elkin et al., “MSC for the improvement of hematopoietic engraftment,” Bone Marrow Transplantation, vol. 45, no. 3, pp. 605–606, 2010. [72] R. M. El Backly and R. Cancedda, “Bone marrow stem cells in clinical application: harnessing paracrine roles and niche mechanisms,” Advances in Biochemical Engineer- ing/Biotechnology, vol. 123, pp. 265–292, 2010. [73] I. McNiece, J. Harrington, J. Turney, J. Kellner, and E. J. Shpall, “Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells,” Cytotherapy, vol. 6, no. 4, pp. 311– 317, 2004. [74] N. Nakao, T. Nakayama, T. Yahata et al., “Adipose tissue- derived mesenchymal stem cells facilitate hematopoiesis in 7 vitro and in vivo,” American Journal of Pathology, vol. 177, no. 2, pp. 547–554, 2010. [75] A. V. Vanikar, H. L. Trivedi, A. Feroze, K. V. Kanodia, S. D. Dave, and P. R. Shah, “Eﬀect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hypo-responsiveness,” International Urology and Nephrology, vol. 43, no. 1, pp. 225– 232, 2010. [76] W. A. Noort, A. B. Kruisselbrink, P. S. In’t Anker et al., “Mes- enchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice,” Experi- mental Hematology, vol. 30, no. 8, pp. 870–878, 2002. [77] I. R. Lemischka, “Microenvironmental regulation of hematopoietic stem cells,” Stem Cells, vol. 15, no. 1, pp. 63–68, 1997. [78] M. Angelopoulou, E. Novelli, J. E. Grove et al., “Cotransplan- tation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice,” Experimental Hematology, vol. 31, no. 5, pp. 413–420, 2003. [79] D. H. Kim, K. H. Yoo, Y. S. Yim et al., “Cotransplanted bone marrow derived mesenchymal stem cells (MSC) enhanced engraftment of hematopoietic stem cells in a MSC-dose dependent manner in NOD/SCID mice,” Journal of Korean Medical Science, vol. 21, no. 6, pp. 1000–1004, 2006. [80] C. L. da Silva, R. Gonc¸alves, K. B. Crapnell, J. M. Cabral, E. D. Zanjani, and G. Almeida-Porada, “A human stro- mal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells,” Experimental Hematology, vol. 33, no. 7, pp. 828–835, 2005. [81] R. Gonc¸alves, C. L. da Silva, J. M. S. Cabral, E. D. Zanjani, and G. Almeida-Porada, “A Stro-1+ human universal stromal feeder layer to expand/maintain human bone marrow hematopoietic stem/progenitor cells in a serum-free culture system,” Experimental Hematology, vol. 34, no. 10, pp. 1353–1359, 2006. [82] N. G. Chung, D. C. Jeong, S. J. Park et al., “Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation,” Interna- tional Journal of Hematology, vol. 80, no. 4, pp. 370–376, 2004. [83] O. Gurevitch, T. B. Prigozhina, T. Pugatsch, and S. Slavin, “Transplantation of allogeneic or xenogeneic bone marrow within the donor stromal microenvironment,” Transplantation, vol. 68, no. 9, pp. 1362–1368, 1999. [84] A. Stanevsky, A. Shimoni, R. Yerushalmi, and A. Nagler, “Cord blood stem cells for hematopoietic transplantation,” Stem Cell Reviews and Reports, vol. 7, pp. 425–433, 2011. [85] M. Battiwalla and P. Hematti, “Mesenchymal stem cells in hematopoietic stem cell transplantation,” Cytotherapy, vol. 11, no. 5, pp. 503–515, 2009. [86] K. Sugiura, H. Hisha, J. Ishikawa et al., “Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vitro,” Stem Cells, vol. 19, no. 1, pp. 46–58, 2001. [87] R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh, “Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes,” Diabetes, vol. 57, no. 7, pp. 1759–1767, 2008. [88] R. E. Newman, D. Yoo, M. A. LeRoux, and A. Danilkovitch- Miagkova, “Treatment of inﬂammatory diseases with mesenchymal stem cells,” Inﬂammation and Allergy-Drug Targets, vol. 8, no. 2, pp. 110–123, 2009.